Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGT NASDAQ:LAB NASDAQ:MDXH NASDAQ:TALK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$21.78-2.4%$20.19$14.57▼$23.56$683.19M0.82193,600 shs182,470 shsLABStandard BioTools$1.28$1.30$0.92▼$2.32$488.95M1.291.23 million shs753,277 shsMDXHMDxHealth$3.48-1.7%$2.79$1.35▼$3.81$167.40M1.49163,797 shs78,135 shsTALKTalkspace$2.55-1.2%$2.58$1.76▼$4.36$432.07M1.091.14 million shs1.69 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics+0.22%+0.04%+9.63%+2.76%+5.33%LABStandard BioTools-5.88%+3.23%-1.92%+18.52%-35.68%MDXHMDxHealth-0.28%-1.67%+33.08%+69.38%+22.92%TALKTalkspace-3.37%-2.64%+3.20%-16.77%+45.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$21.78-2.4%$20.19$14.57▼$23.56$683.19M0.82193,600 shs182,470 shsLABStandard BioTools$1.28$1.30$0.92▼$2.32$488.95M1.291.23 million shs753,277 shsMDXHMDxHealth$3.48-1.7%$2.79$1.35▼$3.81$167.40M1.49163,797 shs78,135 shsTALKTalkspace$2.55-1.2%$2.58$1.76▼$4.36$432.07M1.091.14 million shs1.69 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics+0.22%+0.04%+9.63%+2.76%+5.33%LABStandard BioTools-5.88%+3.23%-1.92%+18.52%-35.68%MDXHMDxHealth-0.28%-1.67%+33.08%+69.38%+22.92%TALKTalkspace-3.37%-2.64%+3.20%-16.77%+45.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGTFulgent Genetics 2.67Moderate Buy$25.3316.31% UpsideLABStandard BioTools 2.00Hold$1.5521.09% UpsideMDXHMDxHealth 3.00Buy$7.00101.15% UpsideTALKTalkspace 3.00Buy$4.5076.47% UpsideCurrent Analyst Ratings BreakdownLatest MDXH, FLGT, LAB, and TALK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025LABStandard BioToolsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold8/13/2025LABStandard BioToolsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$1.558/5/2025FLGTFulgent GeneticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$20.00 ➝ $30.008/4/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$23.00 ➝ $21.007/17/2025LABStandard BioToolsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025MDXHMDxHealthCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGTFulgent Genetics$283.47M2.35N/AN/A$36.92 per share0.59LABStandard BioTools$174.43M2.80N/AN/A$1.27 per share1.01MDXHMDxHealth$90.05M1.83N/AN/A$0.31 per share11.23TALKTalkspace$202.61M2.11$0.01 per share224.73$0.69 per share3.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGTFulgent Genetics-$42.71M-$1.66N/AN/AN/A-16.83%-2.26%-2.10%11/14/2025 (Estimated)LABStandard BioTools-$138.88M-$0.32N/AN/AN/A-69.08%-20.23%-15.32%10/29/2025 (Estimated)MDXHMDxHealth-$38.07M-$0.88N/AN/AN/A-34.98%-374.98%-21.97%11/5/2025 (Estimated)TALKTalkspace$1.15M$0.02127.5613.42N/A1.41%2.48%2.11%11/4/2025 (Estimated)Latest MDXH, FLGT, LAB, and TALK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025MDXHMDxHealth-$0.13-$0.15-$0.02-$0.15$26.60 million$26.60 million8/5/2025Q2 2025TALKTalkspace$0.01-$0.00-$0.01N/A$54.08 million$54.31 million8/1/2025Q2 2025FLGTFulgent Genetics-$0.23$0.07+$0.30-$0.62$76.21 million$81.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGTFulgent GeneticsN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/AMDXHMDxHealthN/AN/AN/AN/AN/ATALKTalkspaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGTFulgent GeneticsN/A6.016.01LABStandard BioToolsN/A5.164.92MDXHMDxHealth13.811.311.22TALKTalkspaceN/A6.516.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGTFulgent Genetics48.06%LABStandard BioTools53.74%MDXHMDxHealthN/ATALKTalkspace57.37%Insider OwnershipCompanyInsider OwnershipFLGTFulgent Genetics33.11%LABStandard BioTools23.16%MDXHMDxHealth1.70%TALKTalkspace23.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGTFulgent Genetics1,31330.61 million20.47 millionOptionableLABStandard BioTools620381.99 million293.53 millionOptionableMDXHMDxHealth30047.29 million46.48 millionNot OptionableTALKTalkspace500167.47 million128.11 millionOptionableMDXH, FLGT, LAB, and TALK HeadlinesRecent News About These CompaniesRemedy Meds acquires Thirty Madison in $500M dealSeptember 8 at 7:23 PM | mobihealthnews.comMJosh Arnold Investment Consultant LLC Acquires New Position in Talkspace, Inc. $TALKSeptember 7 at 6:49 AM | marketbeat.comTalkspace, Inc. $TALK Stock Holdings Lifted by Ancora Advisors LLCSeptember 7 at 5:14 AM | marketbeat.comNuveen LLC Buys New Holdings in Talkspace, Inc. $TALKSeptember 6, 2025 | marketbeat.comAWM Investment Company Inc. Has $10.16 Million Stock Holdings in Talkspace, Inc. $TALKSeptember 5, 2025 | marketbeat.comMetavasi Capital LP Has $2.92 Million Stock Position in Talkspace, Inc. $TALKSeptember 3, 2025 | marketbeat.comTalkspace, Inc. $TALK Shares Purchased by Vanguard Group Inc.September 1, 2025 | marketbeat.comAmerican Century Companies Inc. Sells 565,602 Shares of Talkspace, Inc. $TALKAugust 27, 2025 | marketbeat.comCore Spaces Offers Free Mental Health Services to 30,000 ResidentsAugust 25, 2025 | finance.yahoo.comTalkspace (TALK) Gets a Buy from William BlairAugust 22, 2025 | theglobeandmail.comSCHOOL PHONE BAN: Talkspace CEO speaks on teen mental health and offers tips for parentsAugust 21, 2025 | cbs6albany.comCTalkspace to Participate in Upcoming Investor ConferenceAugust 21, 2025 | globenewswire.comVoss Capital LP Sells 538,277 Shares of Talkspace, Inc. $TALKAugust 21, 2025 | marketbeat.comThe growth of mental health apps and teletherapy: why they’re so popularAugust 20, 2025 | miamitimesonline.comMCity-funded youth mental health therapy services are being used moreAugust 19, 2025 | seattletimes.comSDeutsche Bank AG Has $13.07 Million Stock Holdings in Talkspace, Inc. (NASDAQ:TALK)August 16, 2025 | marketbeat.comTALK | Talkspace Inc. Annual Income Statement | MarketWatchAugust 14, 2025 | marketwatch.comTalkspace adopts Express Access, AI-powered referral infrastructureAugust 12, 2025 | msn.comTalkspace, Inc. (NASDAQ:TALK) is NVP Associates LLC's 2nd Largest PositionAugust 11, 2025 | marketbeat.comFY2025 EPS Estimates for Talkspace Cut by Northland CapmkAugust 11, 2025 | marketbeat.comEarnings To Watch: Talkspace Inc (TALK) Reports Q2 2025 ResultAugust 6, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab Scores Analyst Upgrades, Finalizes Geost TakeoverBy Ryan Hasson | August 13, 2025Rocket Lab Stock: Breakout Brewing or Time for Patience?By Ryan Hasson | August 20, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025Rocket Lab Strengthens Case for Breakout With New Launch PadBy Ryan Hasson | September 3, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025MDXH, FLGT, LAB, and TALK Company DescriptionsFulgent Genetics NASDAQ:FLGT$21.78 -0.54 (-2.42%) Closing price 04:00 PM EasternExtended Trading$21.40 -0.38 (-1.74%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Standard BioTools NASDAQ:LAB$1.28 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.28 +0.00 (+0.39%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.MDxHealth NASDAQ:MDXH$3.48 -0.06 (-1.69%) Closing price 04:00 PM EasternExtended Trading$3.49 +0.01 (+0.29%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Talkspace NASDAQ:TALK$2.55 -0.03 (-1.16%) Closing price 04:00 PM EasternExtended Trading$2.54 -0.01 (-0.39%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talkspace, Inc. operates as a virtual behavioral healthcare company in the United States. The company offers psychotherapy and psychiatry services through its platform to individuals, enterprises, and health plans and employee assistance programs. It provides text, audio, and video-based psychotherapy from licensed therapists. The company offers Talkspace Employee Assistance Program (EAP) and Talkspace Behavioral Health plan (BH) that provides online therapy to members through BH and EAP offerings; and Talkspace for Business for members to access its platform services on a benefit plan paid by the enterprise. It serves its platform through third-party platforms or marketplace, such as Apple App Store and Google Play App Store. Talkspace, Inc. was founded in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
